Clinical Trial Update: Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China [Phase 2]

View source ↗

Summary

A Phase 2 study of VIR-2218 for chronic hepatitis B in Mainland China has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• VIR-2218

Snippet

Sponsor: Brii Biosciences Limited | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2024-08-26